Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Next Previous
Search
Trial Profile

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Exenatide; Semaglutide
  • Indications Obesity
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms LIBERATE-1
  • Sponsors Vivani Medical

Most Recent Events

  • 16 Apr 2025 According to a Vivani Medical media release, announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company and As part of the presentation, Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D., will discuss Vivani's LIBERATE-1 clinical trial.
  • 13 Mar 2025 According to a Vivani Medical media release, Vivani anticipates use of relevant clinical data generated in Australia to support regulatory submissions in other geographies including the United States. Additional guidance regarding future regulatory submissions will be provided as new information becomes available.
  • 13 Mar 2025 According to a Vivani Medical media release, company announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial.Top-line study results expected in mid-2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top